CHIMERIC THERAPEUTICS LIMITED (CHM)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CHM - CHIMERIC THERAPEUTICS LIMITED
FNArena Sector :
NONE
Year End: June
GICS Industry Group : Materials
Debt/EBITDA: N/A
Index:
FNArena Sector : NONE
Year End: June
GICS Industry Group : Materials
Debt/EBITDA: N/A
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.029
23 Apr |
OPEN $0.03 |
HIGH $0.03 |
1,809,714 LOW $0.03 |
-0.002FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2021 | 2022 | 2023 |
|---|---|---|---|
| EPS Basic | xxx | xxx | -6.0 |
| DPS All | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | - |
| Book Value Per Share | xxx | xxx | 1.1 |
| Net Operating Cash Flow | xxx | xxx | -16.3 M |
| Net Profit Margin | xxx | xxx | - |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2021 | 2022 | 2023 |
|---|---|---|---|
| Return on Capital Employed | xxx | xxx | -165.25 % |
| Return on Invested Capital | xxx | xxx | -165.25 % |
| Return on Assets | xxx | xxx | -90.53 % |
| Return on Equity | xxx | xxx | -165.25 % |
| Return on Total Capital | xxx | xxx | -188.01 % |
| Free Cash Flow ex dividends | xxx | xxx | -16.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2021 | 2022 | 2023 |
|---|---|---|---|
| Short-Term Debt | xxx | xxx | - |
| Long Term Debt | xxx | xxx | - |
| Total Debt | xxx | xxx | - |
| Goodwill - Gross | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | 5 M |
| Price To Book Value | xxx | xxx | 3.40 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capex | xxx | xxx | 0.1 M |
| Capex % of Sales | xxx | xxx | - |
| Cost of Goods Sold | xxx | xxx | 1 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | 29 M |
| Research & Development | xxx | xxx | 13 M |
| Investments - Total | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
0.0
No. Of Recommendations
0
CHM STOCK CHART
FNArena News on CHM
| 1 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Chimeric TherapeuticsMay 26 2023 - Small Caps |
| 3 |
Rudi’s View: 2022 Looks Familiar, Though Not Quite The SameDec 02 2021 - Rudi's View |